Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professors Irv Weissman and Ravi Majeti at Stanford University and Professor Paresh Vyas at the MRC Molecular Haematology Unit, are working on an antibody from the Stanford investigators that enables the immune system to detect and kill cancer cells.

Picture of the actin cytoskeleton stained in red.

They are now testing whether it’s safe and effective for use in people with blood cancer. In this week’s blog they tell us how they collaborated across the Atlantic to get public funding for a project that has led to a spin out with multiple backers and a promising clinical trial.

You can read more about the work on the MRC Insight blog

 

This post was originally published on MRC Insight under the title ‘Fighting cancer like an infection’ under CC BY 4.0

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Changes in blood cell production over the human lifetime may hold clues to patterns of disease

A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

PTH infused insulin pump used as an alternative treatment for young patients with ADH1

Queen Mary University of London and OCDEM researchers develop alternative treatment for patients as young as three months.